|
Building customized electronic health records for radiation oncology practices. |
|
|
Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation. |
|
|
Developing innovation therapeutic monoclonal antibody drugs. |
|
|
Neuralstem’s patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of central nervous system diseases and conditions. |
|
|
Seraxis, a private biotech company, is developing a cell therapy to cure insulin-dependent diabetes by replacing the beta cells of the pancreas. Their team of scientists created an induced Pluripotent Stem Cell (iPSC) line, that differentiates robustly into insulin-producing pancreatic cells. These cells are encapsulated to protect them from immune attacks and implanted in relevant models of type-1-diabetes. The safety and efficacy of the Seraxis therapy, SR-01, has been assessed in mice, rat and non-human primates in pre-clinical studies. The well-characterized and stable insulin-producing cells demonstrated a high level of purity, response to glucose challenge and secreted insulin over the 6 months of the studies. Additionally, Seraxis encapsulation technology was shown to efficiently protect these cells from the host immune destruction, while allowing vascularization and nutrition of the cells. In an on-going study, SR-01 has been shown to restore normal glycemic control in immune-competent diabetic rats for more than 3 months. |
|
https://www.shuttlepharma.com/
|
Shuttle Pharmaceuticals develops radiation sensitizing drugs to improve the outcomes of patients undergoing radiation therapy for cancer treatment. Clinical phase drug candidates include ropidoxuridine for sensitizing rapidly growing tumors and doranidazole for sensitizing hypoxic cancers that are resistant to radiation therapy. |
|
|
Developing botulinum toxin and other neurotoxin productions. US Office for Medytox Inc. |
|
|
Therapeutics and diagnostic company focused on pandemic diseases. |
|
|
Immuno-oncology company developing CAR T-Cell Therapy for treatment of Cancer. |
|